Vicapsys Life Sciences, Inc. is a development stage biotechnology company, which advances proprietary localized immune modulator. The company is headquartered in Cumming, Georgia and currently employs 2 full-time employees. The company went IPO on 2001-07-11. VICAPSYN is the Company’s product line that is applied to transplantation therapies and related stem-cell applications in the transplantation field. The lead product candidate embodiment in transplantation therapy to treat Type 1 Diabetes (T1D) is an encapsulated human islet cell cluster that is intended to restore normal glucose control when implanted into the peritoneal cavity of a patient. The company also develops another product candidate line based on CXCL12 with the trade name of VYBRIN. The clinical applications of VYBRIN are being explored in several areas, including prevention of post-surgical adhesions in abdominal surgery, and others.
How did VICP's recent EPS compare to expectations?
The most recent EPS for Vicapsys Life Sciences Inc is $, expectations of $.
How did Vicapsys Life Sciences Inc VICP's revenue perform in the last quarter?
Vicapsys Life Sciences Inc revenue for the last quarter is $
What is the revenue estimate for Vicapsys Life Sciences Inc?
According to of Wall street analyst, the revenue estimate of Vicapsys Life Sciences Inc range from $ to $
What's the earning quality score for Vicapsys Life Sciences Inc?
Vicapsys Life Sciences Inc has a earning quality score of B+/51.449146. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Vicapsys Life Sciences Inc report earnings?
Vicapsys Life Sciences Inc next earnings report is expected in
What are Vicapsys Life Sciences Inc's expected earnings?
Vicapsys Life Sciences Inc expected earnings is $, according to wall-street analysts.
Did Vicapsys Life Sciences Inc beat earnings expectations?
Vicapsys Life Sciences Inc recent earnings of $ expectations.